Day One Biopharmaceuticals, Inc. (DAWN)

Market Cap	1.01B
Revenue (ttm)	n/a
Net Income (ttm)	-174.52M
Shares Out	87.04M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	770,546
Open	11.82
Previous Close	11.60
Day's Range	11.52 - 12.23
52-Week Range	9.67 - 25.77
Beta	-1.83
Analysts	Buy
Price Target	38.14 (+229.36%)
Earnings Date	Nov 6, 2023

About DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceutic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 133
• Stock Exchange: NASDAQ
• Ticker Symbol: DAWN

Analyst Forecast

According to 8 analysts, the average rating for DAWN stock is "Buy." The 12-month stock price forecast is $38.14, which is an increase of 229.36% from the latest price.

Price Target

$38.14

(229.36% upside)

Analyst Consensus: Buy